Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859589 | 0.89 | KIF11 (0.43) | KIF11GPR84FFAR1KMT2AMEN1 | |
| SCHEMBL7541639 | 0.81 | KIF11 (0.40) | KIF11NPC1RAB9A | |
| SCHEMBL7147418 | 0.79 | CNR1 (0.40) | CNR1CNR2 | |
| SCHEMBL7144172 | 0.79 | CNR1 (0.40) | CNR1CNR2 | |
| SCHEMBL15212062 | 0.77 | KIF11 (0.40) | KIF11CNR1CNR2NPC1RAB9A | |
| SCHEMBL6855010 | 0.77 | L3MBTL1 (0.39) | KIF11CNR1CNR2KMT2ANPC1 | |
| SCHEMBL15212175 | 0.75 | NFE2L2 (0.39) | KIF11CNR1CNR2KMT2ANPC1 | |
| SCHEMBL5133757 | 0.74 | NFE2L2 (0.40) | KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL8457737 | 0.73 | KMT2A (0.42) | USP2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL7144402 | 0.72 | MEN1 (0.42) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-20230089442-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-23 | — | — | US | disclosed |
| US-11608355-B2 | Technologies for oligonucleotide preparation | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-21 | — | — | US | disclosed |
| EP-3941924-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | Wave Life Sciences Ltd. (SG) | 2022-01-26 | — | — | EP | disclosed |
| CN-113748116-A | Techniques useful for oligonucleotide preparation | 波涛生命科学有限公司 | 2021-12-03 | — | — | CN | disclosed |
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| EP-3684755-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | Wave Life Sciences Ltd. (SG) | 2020-07-29 | — | — | EP | disclosed |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-23 | — | — | US | disclosed |
| CN-111108096-A | Oligonucleotide preparation technology | 波涛生命科学有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019055951-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2019-03-21 | — | — | WO | disclosed |
| US-7135564-B1 | Reusable solid support for oligonucleotide synthesis | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2006-11-14 | — | — | US | disclosed |
| EP-1091972-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001711-A1 | REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608355-B2 | Technologies for oligonucleotide preparation | POLRMT, DCLRE1B, RNGTT | KIF11 185/4885CNR1 4773/4885CNR2 4829/4885 |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | KIF11 185/4885CNR1 4773/4885CNR2 4829/4885 |
| US-20230089442-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, POLM | KIF11 385/4885CNR1 4722/4885CNR2 4820/4885 |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | KIF11 185/4885CNR1 4773/4885CNR2 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.